Dopamine receptor D2. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Olanzapine CHEMBL715 |
D2-like dopamine receptor antagonist Antagonist Small molecule |
✓ Both | 19 |
| Quetiapine CHEMBL716 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 11 |
| Cabergoline CHEMBL1201087 |
Dopamine D2 receptor agonist Agonist Small molecule |
✓ Both | 9 |
| Clozapine CHEMBL42 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 8 |
| Risperidone CHEMBL85 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 8 |
| Aripiprazole CHEMBL1112 |
Dopamine D2 receptor partial agonist Partial agonist Small molecule |
✓ Both | 7 |
| Metoclopramide CHEMBL86 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 7 |
| Cariprazine CHEMBL2028019 |
Dopamine D2 receptor modulator Modulator Small molecule |
✓ Both | 5 |
| Lumateperone CHEMBL3306803 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 5 |
| Pramipexole CHEMBL301265 |
D2-like dopamine receptor agonist Agonist Small molecule |
✓ Both | 5 |
| Brexpiprazole CHEMBL2105760 |
Dopamine D2 receptor partial agonist Partial agonist Small molecule |
✓ Both | 3 |
| Dopamine CHEMBL59 |
Full agonist at DRD2 Primary target Small molecule |
Guide to Pharmacology only | 3 |
| Iloperidone CHEMBL14376 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 3 |
| Pridopidine CHEMBL596802 |
Dopamine D2 receptor modulator Modulator Small molecule |
ChEMBL only | 3 |
| Domperidone CHEMBL219916 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 2 |
| Haloperidol CHEMBL54 |
D2-like dopamine receptor inverse agonist Inverse agonist Small molecule |
✓ Both | 2 |
| Lurasidone CHEMBL1237021 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
✓ Both | 2 |
| Paliperidone Palmitate CHEMBL2107360 |
Dopamine D2 receptor antagonist Antagonist Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Major depressive disorder | 9 | Phase 3 |
| Bipolar I disorder | 7 | Phase 3 |
| Bipolar disorder | 7 | Phase 3 |
| Depressive disorder | 6 | Phase 3 |
| Schizoaffective disorder | 6 | Phase 3 |
| Alzheimer disease | 5 | Phase 3 |
| Irritability | 5 | Phase 3 |
| Borderline personality disorder | 4 | Phase 3 |
| Intellectual disability | 4 | Phase 3 |
| Alcohol dependence | 4 | Phase 3 |
| Post-traumatic stress disorder | 4 | Phase 3 |
| Agitation | 3 | Phase 3 |
| Cognitive impairment | 3 | Phase 3 |
| Huntington disease | 3 | Phase 3 |
| Self-injurious behavior | 3 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
